newsfilter
← Latest News
Business Wire·

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

Preclinical data suggests novel mRNA-launched eVLPs ("MLE") generate significantly enhanced B-cell and T-cell responses compared to mRNA-expression of antigens alone In addition to immunologic benefits, new MLE